Ipsen announces change in R&D leadership: Howard Mayer to

 PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment...

Related Keywords

China ,Germany ,Shanghai ,Massachusetts ,United States ,Saclay ,France General ,France ,Cambridge ,Cambridgeshire ,United Kingdom ,Paris ,Switzerland ,American ,French ,David Loew ,Ioana Piscociu ,Christelle Huguet ,Ipsen Euronext ,Nicolas Bogler ,Howard Mayer ,Amy Wolf ,French University Diploma In Technology ,Leadership Team ,Institute Pasteur ,Head Of Research ,Early Development ,Business Development ,Pfizer ,Inc Zebiai Therapeutics ,Executive Vice President ,Executive Leadership Team ,Chief Executive Officer ,Senior Vice President ,External Innovation ,Rare Disease ,Executive Leadership ,Chief Scientific Officer ,X Chem Inc ,Global Head ,French University Diploma ,European Engineering ,Sponsored Level ,American Depositary Receipt ,Corporate Brand Strategy ,French Autorit ,Des March ,Universal Registration Document ,Paris Stock Exchange Ipn ,Ipsen Pharma ,